Gut-Immune-Brain Axis Clinical Trial for Parkinson's Disease

Migration, Crosslink

📖

Gut-Immune-Brain Axis Clinical Trial for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-gut-immune-brain-pd-tria

📖 Wiki Page

mechanism1588 wordssynced 2026-04-02

Gut-Immune-Brain Axis Clinical Trial for Parkinson's Disease

Trial Overview

flowchart TD Gut_Immune_Brain_Axis_Clinical["Gut-Immune-Brain Axis Clinical Trial for Parkins"] Gut_Immune_Brain_Axis_Clinical["Gut-Immune-Brain"] Gut_Immune_Brain_Axis_Clinical -->|"related to"| Gut_Immune_Brain_Axis_Clinical style Gut_Immune_Brain_Axis_Clinical fill:#81c784,stroke:#333,color:#000 Gut_Immune_Brain_Axis_Clinical["Axis"] Gut_Immune_Brain_Axis_Clinical -->|"related to"| Gut_Immune_Brain_Axis_Clinical style Gut_Immune_Brain_Axis_Clinical fill:#81c784,stroke:#333,color:#000 Gut_Immune_Brain_Axis_Clinical["Parkinson"] Gut_Immune_Brain_Axis_Clinical -->|"related to"| Gut_Immune_Brain_Axis_Clinical style Gut_Immune_Brain_Axis_Clinical fill:#81c784,stroke:#333,color:#000 style Gut_Immune_Brain_Axis_Clinical fill:#4fc3f7,stroke:#333,color:#000

This clinical trial tests gut-immune axis modulation in [Parkinson's disease](/diseases/parkinsons-disease) patients using a combination of prebiotic/probiotic/Vitamin D therapy. The study is based on growing evidence that the [gut-brain axis](/mechanisms/neuroinflammation) plays a critical role in [neurodegeneration](/diseases/parkinsons-disease) and that [alpha-synuclein](/proteins/alpha-synuclein) pathology may originate in the enteric nervous system before spreading to the brain["@braak2003"][@braak2003a].

Rationale and Background

The Gut-Brain Axis in Parkinson's Disease

...

Gut-Immune-Brain Axis Clinical Trial for Parkinson's Disease

Trial Overview

Mermaid diagram (expand to render)

This clinical trial tests gut-immune axis modulation in [Parkinson's disease](/diseases/parkinsons-disease) patients using a combination of prebiotic/probiotic/Vitamin D therapy. The study is based on growing evidence that the [gut-brain axis](/mechanisms/neuroinflammation) plays a critical role in [neurodegeneration](/diseases/parkinsons-disease) and that [alpha-synuclein](/proteins/alpha-synuclein) pathology may originate in the enteric nervous system before spreading to the brain["@braak2003"][@braak2003a].

Rationale and Background

The Gut-Brain Axis in Parkinson's Disease

The [gut-brain axis](/mechanisms/neuroinflammation) in Parkinson's disease involves complex bidirectional communication between the intestinal microbiome, the immune system, and the central nervous system. This connection has become increasingly recognized as a key factor in PD pathogenesis[@sampson2016][@poewe2022].

Evidence for Gut Origin of PD

Several lines of evidence support the hypothesis that Parkinson's disease may originate in the gut:

Gastrointestinal Symptoms: [Parkinson's disease](/diseases/parkinsons-disease) patients often exhibit gastrointestinal symptoms, particularly constipation, years before motor symptoms appear[@savica2010][@postuma2015]
Alpha-Synuclein Pathology: [Alpha-synuclein](/proteins/alpha-synuclein) aggregates (the key pathological protein in PD) have been found in the enteric nervous system of PD patients, and these aggregates may travel via the vagus nerve to the brain[@braak2003b][@shannon2013]
Genetic Factors: [LRRK2](/genes/lrrk2) mutations (one of the most common genetic causes of PD) are expressed in immune cells and may affect immune function[@gardet2010][@wandinger2011]
Microbiome Alterations: Altered gut microbiome composition has been consistently reported in PD patients compared to healthy controls[@keshavarzian2015][@hillburns2017]

The Microbiome-Gut-Brain Communication

The gut microbiome communicates with the brain through multiple pathways:

Vagal Afferents: The vagus nerve provides direct neural connection between gut and brain

Metabolites: Short-chain fatty acids (SCFAs) produced by gut bacteria cross the blood-brain barrier

Immune System: Gut-associated lymphoid tissue (GALT) primes systemic immune responses

Endocrine Pathways: Gut hormones and neurotransmitters enter systemic circulation

Role of Inflammation in PD

Chronic [neuroinflammation](/mechanisms/neuroinflammation) is a hallmark of Parkinson's disease, characterized by activated microglia and elevated pro-inflammatory cytokines[@hirsch2012][@tansey2022]:

IL-1β: Elevated in PD brains and CSF
IL-6: Associated with disease progression
TNF-α: Found in substantial amounts in substantia nigra of PD patients
CRP: Systemic inflammation marker elevated in PD

The gut microbiome influences systemic inflammation through microbial metabolite production and immune cell modulation[@erny2015][@burokas2017].

Vitamin D and Neuroprotection

Vitamin D has multiple potential neuroprotective effects:

Modulation of microglia activation
Protection against oxidative stress
Regulation of calcium homeostasis
Support for neurotrophic factor production
Immunomodulatory properties

Vitamin D deficiency has been associated with increased PD risk and severity[@evatt2008][@fullard2010].

Study Design

Phase and Duration

Phase: Phase 2, randomized, double-blind, placebo-controlled

Duration: 30 months (including 6-month follow-up after treatment period)

Enrollment

Target Enrollment: 120 [Parkinson's disease](/diseases/parkinsons-disease) patients

Power Calculation: 80% power to detect 4-point difference in MDS-UPDRS Part III at α=0.05

Arms

Active Treatment: Prebiotic fiber + Probiotic + Vitamin D3

Placebo Control: Matching placebo

Randomization

Stratified randomization by:

Disease duration (< 5 years vs ≥ 5 years)
Hoehn & Yahr stage (1-2 vs 3)
Vitamin D status (deficient vs sufficient)

Inclusion Criteria

Age 40-80 years
Diagnosis of [Parkinson's disease](/diseases/parkinsons-disease) according to UK Brain Bank criteria
Hoehn & Yahr stage 1-3
Stable PD medications for at least 4 weeks prior to enrollment
No significant cognitive impairment (MoCA ≥ 24)
Able to provide informed consent
Willingness to comply with study procedures

Exclusion Criteria

Recent antibiotics (within 4 weeks)
Probiotic or prebiotic supplementation (within 4 weeks)
Gastrointestinal disorders (IBD, celiac disease, IBS requiring medication)
Immunocompromised state
Serum 25-hydroxyvitamin D > 100 ng/mL (to avoid vitamin D toxicity)
History of hypercalcemia
Current participation in other clinical trials
Significant medical conditions that may interfere with participation
Pregnancy or breastfeeding

Endpoints

Primary Endpoints

Motor Symptoms: Change in MDS-UPDRS Part III (motor score) from baseline to 24 months

Inflammatory Biomarkers: Change in serum IL-6, TNF-α, and CRP from baseline to 24 months

Secondary Endpoints

Gut Microbiome: Change in gut microbiome composition (alpha and beta diversity, relative abundance of key taxa)

Non-Motor Symptoms: Change in Non-Motor Symptoms Scale (NMSS)

Quality of Life: Change in PDQ-39

Vitamin D Status: Change in serum 25-hydroxyvitamin D levels

Cognitive Function: Change in MoCA score

Motor Fluctuations: Change in ON-OFF time diary

Constipation: Change in bowel movement frequency

Exploratory Endpoints

CSF Biomarkers: Subset analysis of α-synuclein, tau, and neurofilament light chain in cerebrospinal fluid

Microbiome Metabolites: Fecal SCFA levels

Immune Cell Phenotyping: Peripheral blood mononuclear cell analysis

Intervention Details

Active Arm

| Component | Dose | Timing |
|-----------|------|--------|
| Prebiotic fiber (inulin-type) | 10g/day | Once daily with breakfast |
| Probiotic (Bifidobacterium + Lactobacillus) | 10^10 CFU/day | Once daily |
| Vitamin D3 | 4000 IU/day | Once daily |

Placebo Arm

Matching placebo for each component:

Maltodextrin for prebiotic
Heat-killed probiotic for probiotic
Lookalike capsule for vitamin D

Adherence Monitoring

Daily diary completion
Pill counts at each visit
Serum probiotic quantification (subset)

Mechanism of Action

The intervention targets multiple pathways in the [gut-brain axis](/mechanisms/neuroinflammation):

1. Gut Microbiome Modulation

Prebiotics (inulin-type fructans) and probiotics work synergistically to:

Promote beneficial bacteria (Bifidobacteria, Lactobacilli)
Increase short-chain fatty acid (SCFA) production
Reduce intestinal permeability (leaky gut)
Decrease endotoxin translocation

SCFAs, particularly butyrate, have anti-inflammatory properties and can cross the blood-brain barrier to modulate microglia[@bologna2021][@silva2020].

2. Immune System Regulation

Certain probiotic strains can modulate [neuroinflammation](/mechanisms/neuroinflammation) by:

Reducing pro-inflammatory cytokines (IL-6, TNF-α)
Increasing anti-inflammatory cytokines (IL-10)
Promoting regulatory T cells
Modulating microglia activation

3. Vitamin D Immunomodulation

Vitamin D exerts neuroprotective effects through:

Inhibition of microglia activation
Reduction of nitric oxide production
Protection against oxidative stress
Support for neurotrophic factor production (BDNF)
Regulation of autophagy

4. Combined Effect Hypothesis

The combination approach targets multiple mechanisms simultaneously, potentially producing synergistic effects.

Statistical Analysis

Sample Size and Power

Sample size: 60 per arm
Expected dropout: 15%
Power: 80% (α=0.05)
Effect size: 0.5 (medium effect)

Primary Analysis

Mixed-effects model with repeated measures (MMRM):

Fixed effects: treatment, time, treatment × time
Random effect: participant
Covariates: baseline value, disease duration, age

Secondary Analyses

Per-protocol analysis
Subgroup analyses by baseline vitamin D status, microbiome composition
Sensitivity analyses for missing data

Analysis Plan

Intention-to-treat (ITT) population
Safety population: all participants who received at least one dose
Per-protocol population: participants with ≥ 80% adherence

Budget

| Category | Cost (USD) |
|----------|------------|
| Personnel (PI, coordinators, nurses) | $400,000 |
| Study drug (active and placebo) | $150,000 |
| Biomarker assays | $200,000 |
| Microbiome sequencing | $180,000 |
| MRI imaging (subset) | $120,000 |
| Clinical laboratory | $80,000 |
| Administrative costs | $120,000 |
| Contingency (15%) | $187,000 |
| Total | $1,437,000 |

Timeline

| Month | Milestone |
|-------|-----------|
| 0-3 | IRB approval, regulatory submissions, site setup |
| 3-6 | Patient recruitment initiation |
| 6-18 | Active patient recruitment |
| 18-24 | Treatment period for last-enrolled patient |
| 24-27 | Follow-up assessments |
| 27-30 | Data analysis, manuscript preparation |
| 30+ | Publication, regulatory reporting |

Expected Outcomes and Risks

Expected Outcomes

Reduced systemic inflammation: Decrease in IL-6, TNF-α, CRP
Improved motor symptoms: Lower MDS-UPDRS Part III scores
Altered gut microbiome: Increased SCFA-producing bacteria
Potential disease modification: Slower motor progression

Risks and Mitigations

Gastrointestinal discomfort: Start with lower dose, titrate up

Vitamin D toxicity: Monitor serum levels regularly

Probiotic infection: Use strains with excellent safety profiles

Placebo response: Ensure proper blinding

[Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation)
[Alpha-Synuclein Aggregation in PD](/mechanisms/alpha-synuclein-pd)
[Gut-Brain Axis](/entities/gut-brain-axis)
[Microbiome and Neurodegeneration](/mechanisms/microbiome-neurodegeneration)
[Vitamin D Signaling in Neuroprotection](/mechanisms/vitamin-d-neuroprotection)
[LRRK2 and Immune Function](/genes/lrrk2)

[Clinical Trials in Parkinson's Disease](/clinical-trials/parkinsons)
[Promising Clinical Trials in Neurodegenerative Diseases](/clinical-trials/promising)
[Linked Clinical Trials (Cure Parkinson's Trust)](/clinical-trials/linked)

References

[Braak et al., Staging of brain pathology related to sporadic Parkinson's disease (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14532271/)

[Braak et al., Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be initiated (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12621350/)

[Sampson et al., Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27739530/)

[Poewe et al., Parkinson's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36000812/)

[Savica et al., Medical records and longitudinal studies: Do they tell the same story about the emergence of Parkinson's disease? (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20306062/)

[Postuma et al., Identifying prodromal Parkinson's disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26487579/)

[Braak et al., Staging of brain pathology related to sporadic Parkinson's disease (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14532271/)

[Shannon et al., Intestinal dysmotility contributes to alpha-synuclein pathology (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24312225/)

[Gardet et al., LRRK2 is expressed in B cells (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20077548/)

[Wandinger et al., LRRK2 and immune cells (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21344673/)

[Keshavarzian et al., Colonic inflammation in Parkinson's disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25561235/)

[Hill-Burns et al., Parkinson's disease and Parkinson's disease medications have distinct signatures in the microbiome (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28028168/)

[Hirsch et al., Neuroinflammation in Parkinson's disease (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22293358/)

[Tansey et al., Neuroinflammatory mechanisms in Parkinson's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35130841/)

[Erny et al., Host microbiota constantly control maturation and function of microglia (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25594188/)

[Burokas et al., Targeting the microbiota-gut-brain axis (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28220784/)

[Evatt et al., Prevalence of vitamin D insufficiency (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18684022/)

[Fullard et al., Vitamin D and the risk of Parkinson's disease (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20081827/)

[Bologna et al., Short chain fatty acids and neuroinflammation (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34160447/)

[Silva et al., Butyrate and neuroinflammation (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32799459/)

📖 View canonical wiki page →

Related Entities

mechanisms-gut-immune-brain-pd-trial

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-gut-immune-brain-pd-trial
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1d355ec8e081
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-gut-immune-brain-pd-trial'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

119

Outgoing

130

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Gut-Immune-Brain Axis Clinical Trial for Parkinson's Disease

Gut-Immune-Brain Axis Clinical Trial for Parkinson's Disease

Trial Overview

Rationale and Background

The Gut-Brain Axis in Parkinson's Disease

Gut-Immune-Brain Axis Clinical Trial for Parkinson's Disease

Trial Overview

Rationale and Background

The Gut-Brain Axis in Parkinson's Disease

Evidence for Gut Origin of PD

The Microbiome-Gut-Brain Communication

Role of Inflammation in PD

Vitamin D and Neuroprotection

Study Design

Phase and Duration

Enrollment

Arms

Randomization

Inclusion Criteria

Exclusion Criteria

Endpoints

Primary Endpoints

Secondary Endpoints

Exploratory Endpoints

Intervention Details

Active Arm

Placebo Arm

Adherence Monitoring

Mechanism of Action

1. Gut Microbiome Modulation

2. Immune System Regulation

3. Vitamin D Immunomodulation

4. Combined Effect Hypothesis

Statistical Analysis

Sample Size and Power

Primary Analysis

Secondary Analyses

Analysis Plan

Budget

Timeline

Expected Outcomes and Risks

Expected Outcomes

Risks and Mitigations

Related Mechanisms and Pathways

Related Clinical Trials

See Also

References

💬 Discussion